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Abstract 
Biomarkers of neurodegenerative disorders are needed to assist in diagnosis, to monitor 
disease progression and therapeutic interventions, and to provide insight into disease 
mechanisms. One route to identify such biomarkers is by proteomic and peptidomic analysis 
of cerebrospinal fluid (CSF).  
In the current study, we performed an in-depth analysis of the human CSF endopeptidome to 
establish an inventory that may serve as a basis for future targeted biomarker studies. High-
pH reversed-phase HPLC was employed for peptide fractionation followed by low-pH nano-
LC-MS analysis. Different software programs and scoring algorithms for peptide 
identification were employed and compared. 
A total of 18,031 endogenous peptides were identified (FDR = 1%), increasing the number of 
known CSF peptides 10-fold compared to previous studies. The peptides were derived from 
2,053 proteins of which more than 60 have been linked to neurodegeneration. Notably, among 
the findings were six peptides derived from microtubule-associated protein tau, three of which 
span the diagnostically interesting threonine-181. Also, 213 peptides from amyloid precursor 
protein (APP), 58 of which were partially or completely within the sequence of amyloid β 1-
40/42, as well as 109 peptides from apolipoprotein E, spanning sequences that discriminate 
between the E2/E3/E4 isoforms of the protein. 
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Introduction 
Analysis of cerebrospinal fluid (CSF) is valuable to study neurodegenerative disorders (1). 
Research on diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) would 
benefit greatly from new biomarkers that can aid in diagnosis, be used for monitoring disease 
progression, and provide insight into the disease mechanisms. As new disease-modifying 
therapies are being developed, for example against AD (2), there will be an increased need for 
biomarkers that enable earlier and more accurate diagnosis, as well as to provide means to 
monitor disease progression and response to treatment. 
Produced as an ultra-filtrate of blood in the ventricles and around the blood vessels of the 
central nervous system (CNS), CSF circulates around the brain and the spinal cord and is 
drained into the blood, with a turnover time of approximately 8 h (3). A multitude of 
molecules shed by cells in the brain are present in CSF, and thus, many processes in the CNS 
are dynamically reflected in the molecular composition of the CSF. Approximately 20% of 
the protein content is derived from the CNS through the interstitial fluid and the remainder 
can be traced to plasma constituents passing the blood-brain barrier (4-9). Shotgun proteomic 
studies of CSF have led to the identification of biomarker candidates of several 
neurodegenerative disorders, including AD, PD, and multiple sclerosis (10). 
Studies by our group and others have revealed that CSF, besides proteins, contains many 
endogenous peptides (11-16). Their concentration being dependent on a variety of processes, 
such as enzymatic protein processing, secretion, and aggregation, these peptides may convey 
valuable biomarker information. Such information may obviously be lost when following the 
currently standard analytical strategy in proteomics of digesting the sample proteins with 
trypsin and basing protein quantification on measurement of tryptic peptides. 
From an analytical point of view, endogenous peptides are attractive: circumventing 
proteolytic digestion eliminates a source of analytical variability and reduces cost and sample 
preparation time, which are important aspects for establishing assays for clinical research and 
routine settings. Furthermore, endogenous peptides can be readily isolated by molecular-
weight ultrafiltration from the high-abundant proteins that make up the bulk of the CSF 
protein contents, such as albumin and immunoglobulins, allowing a larger volume of CSF 
peptide extract to be used for LC-MS analysis and thereby enabling detection of lower-
abundant peptides. 
In a pilot study we identified quantitative differences in endogenous peptides in AD patients 
compared to controls (17), suggesting their potential as biomarkers. In a recent study, we used 
endopeptidomics to detect changes in the abundance of endogenous CSF peptides in healthy 
individuals following treatment with the -secreatase inhibitor semagacestat demonstrating 
target engagement (18). 
In order to further investigate the potential of endogenous peptides in CSF as biomarkers, the 
aim of the current study was to expand the known CSF peptidome to include also more low-
abundant peptides. Our approach was to implement a step of peptide pre-fractionation to 
allow increased CSF volume to be used for LC-MS analysis, and employing software that 
employs different algorithms for peptide identification and scoring of spectrum matches. 
 
Experimental Procedures 
Participants and sampling of cerebrospinal fluid 
Cerebrospinal fluid was sampled from one patient diagnosed with hydrocephalus undergoing 
evaluation at Lund University Hospital, Lund, Sweden; as well as from CSF pooled from five 
individuals undergoing evaluation at the Clinical Neurochemistry Laboratory, Sahlgrenska 
University Hospital, Mölndal, Sweden. Sampling was performed by lumbar puncture in 
accordance with a standardised protocol previously developed on site. Non-soluble material, 
cells and cell debris in the CSF were removed by centrifugation at 2000 x g and +4 °C for 10 
min. Surplus CSF from patients undergoing clinical evaluation was used for this project after 
de-identification, as approved by the regional ethics committee at the University of 
Gothenburg.  
Materials 
Ammonium bicarbonate (AmBic) [40867-F], 25% ammonium hydroxide [30501], 1 M 
triethylammonium bicarbonate pH 8.5 (TEAB) [T7408], 8 M guanidinuim hydrochloride 
(Gua-HCl) [G9824], ≥98% sodium deoxycholic acid (Na-DOC) [30970], ≥98% tris(2-
carboxyethyl)phosphine (TCEP) [C4706], ≥ 99% iodacetamide (IAA) [I1149], 99% 
trifluoracetic acid (TFA) [T6508] and 98% formic acid (FA) [56302-F] were all acquired 
from Sigma-Aldrich; HPLC-gradient grade Far-UV acetonitrile (AcN) [A998] and iso-
propanol [A520] from Fisher Scientific; trypsin acquired from Promega [V5111]]; Amicon 
Ultra-15 Centrifugal Filter Units 30 kDa Molecular weight cut-off (MWCO) ultracentrifuge-
filters [UFC903024] were obtained from Merck Millipore and Sep-Pak® Vac 1cc (100mg) 
C18 cartridges [WAT023590]was obtained from Waters. 
CSF sample preparation – endogenous peptides 
CSF peptide extracts were prepared according to a previously described protocol (19), 
modified to accommodate a larger sample volume. Briefly, 1.5 ml aliquots of CSF were 
thawed at room temperature (RT), vortexed gently, and transferred to 15 ml Falcon tubes. 
Aliquots of 1 M TEAB (250 µl) and 8 M GuaHCl (750 µl) were added and the samples were 
vortexed gently. Reduction of protein/peptide disulphides was attained by addition of a 
solution of 200 mM TCEP (60 µl), 300 mM TEAB (60 µl) followed by 1 h incubation at +55 
°C under gentle agitation. The samples were subsequently alkylated by addition of 60 µl 400 
mM IAA (aq) followed by 30 min incubation at RT in darkness. The samples were diluted by 
addition of 2.38 ml water (MilliQ) to a total volume of 5 ml and vortexed. 
Isolation of endogenous peptides was performed by ultrafiltration using 30 kDa MWCO filter devices. 
The filters were conditioned by adding a solution of 100 mM TEAB, 3 M Gua-HCl (5 ml) and 
centrifuging at 2,500 x g for 20 min at RT, discarding the flow-through. The samples were then loaded 
and centrifuged (2,500 x g for 45 min, RT). To improve recovery, 50 mM AmBic (3 ml) were loaded, 
spun through (RT, 2,500 x g for 20 min) and pooled with the filtrate.  
The sample was acidified (final pH ≈ 3) by titration with 0.1% TFA and subsequently 
desalted by SPE (SEP-Pak C18), operated using a vacuum chamber. The cartridge was 
conditioned with 2 x 1 ml 84% AcN, 0.1% TFA, and equilibrated by 2 x 1 ml 0.1% TFA, 
after which the sample was loaded, washed with 2 x 1 ml 0.1% TFA and subsequently eluted 
with 1 ml 84% AcN, 0.1% TFA. Finally the eluate solvents were evaporated in a vacuum 
concentrator and at –80 °C. 
CSF sample preparation – tryptic peptides 
For comparing the identification rates of endogenous and tryptic peptides, an aliquot of the 
CSF sample from the hydrocephalus patient was digested with trypsin. CSF (100 µl) was 
thawed at RT, vortexed gently and transferred to a 1.5 ml Eppendorf tube. Aliquots of 1 M 
TEAB (16.7 µl) and 3.3% Na-DOC (50 µl) were added and the sample was vortexed. 
Reduction of protein disulphides was performed by adding an aliquot of 200 mM TCEP, 300 
mM TEAB (4 µl) followed by 1 h incubation at +55 °C under gentle agitation. Cysteines were 
alkylated by addition of 400 mM IAA (4 µl) followed by 30 min incubation at RT in 
darkness. Trypsin (Promega, 20 µg) was dissolved in 50 mM acetic acid (100 µl) and pre-
incubated for 15 min at 37 °C. A 25 µl aliquot of the solution was transferred to the sample, 
which was incubated 12 h at 37 °C. The sample was subsequently desalted, concentrated, and 
stored as described above. 
Alkaline Reverse-Phase HPLC Separation and Fraction Concatenation 
HpH-RPLC fractionation was performed according to the method of Bath et al (20) with 
minor method alterations, using a Ultimate 3000 HPLC system (Thermo) equipped with an 
integrated fraction collector adapted for 96-well deep well plates. Endogenous peptide 
extracts (from 1.5 ml CSF) were dissolved in 2.5 mM NH3(aq) and 2% AcN (15 µl), and 
separated over an XBridge Peptide BEH C18 Column, 130 Å . The mobile phases consisted of 
(A) pure water; (B) 84% AcN; and (C) 25 mM NH3(aq). Buffer C was made fresh at the start 
of each trial and kept on ice to minimize NH3(aq) decomposition/evaporation. The LC was 
operated at a constant flow of 100 µl/min with a constant concentration of 10% Buffer C, and 
using the following gradient: t (min)=0, %B=2%; t=4, B=2%; t=50, B=90%; t=66, B=90%; 
t=67, B=2%; t=76, B=2%. Fraction collection was started at t=4 min, collecting 72 one-
minute fractions in a cycling pattern over 24 wells in a 96-well deep-well plate, resulting in 3 
concatenated fractions per well. The fractions were further concatenated by combining the 
contents of well 1 and 13, 2 and 14, 3 and 15 etc., resulting in 12 samples, each containing six 
of the original fractions. The fractions were subsequently split in two aliquots, vacuum 
concentrated and stored at –80 °C until LC-MS analysis. 
LC-MS 
Chromatography was performed on an Ultimate 3000 RSLC nano system (Thermo) in trap 
column configuration (trap column: Acclaim® PepMap 100 (Thermo), 75 µm x 2 cm, C18, 
100 Å pore size, 3 µm particle size; separation column: Acclaim® PepMap C18, 75 µm x 500 
mm, 100Å pore size, 2 µm particle size). The mobile phases were (A) 0.1% FA and (B) 84% 
AcN, 0.1% FA. Sample aliquots corresponding to 750 µl CSF were dissolved in 0.05% TFA, 
2% AcN (6 µl) (loading buffer). 5 µl were loaded at 5 µl/min using 0.05% TFA, 2% AcN. 
The following gradient was used: t (min) =0, B=2%; t=10, B=2%; t=11, B=7%; t=100, 
B=26%; t=170, B=45%; t=175, B=80%; t=181, B=2%; t=210, B=2%. The LC was connected 
to an Orbitrap Fusion™ Tribrid™ mass spectrometer (Thermo) via a FlexiSpray nano-ESI 
interface (Thermo). Full scan spectra were recorded in MS mode at a resolution setting of 
120,000 (2.0e5 AGC target) over the m/z range 350-1400. The mass spectrometer was 
operated in the data-dependent acquisition mode, recording MS/MS spectra from the top ten 
most intense peaks with m/z > 150 and within the intensity range 1.0e4-1.0e5 were selected 
for fragment ion analysis. Precursor ions were isolated using a quadrupole isolation window 
of 3 m/z. Dynamic exclusion was used, with an exclusion time of 15 s and an m/z tolerance of 
±10 ppm. Fragmentation was performed in the higher-collision energy dissociation (HCD) 
cell (29% collision energy) and MS/MS acquisitions were recorded in the orbitrap at a 
resolution setting of 30,000 (5.0e4 AGC target value). A replicate analysis was performed of 
each fraction. 
Peptide identification 
Peptide identification was performed using Mascot v2.4 (Matrix Science), SequestHT 
(Thermo), and PEAKS Studio v7.5 (Bioinformatic Solutions Inc.). The following settings 
were used for all three programs unless otherwise specified: database: UniProt_SwissProt 
[version2015_11]; taxonomy: homo sapiens; enzyme: none (trypsin for digested samples); 
max. missed cleavages: 0 (endogenous peptides), 2 (tryptic peptides); instrument (Mascot 
only): ESI-Trap; min. peptide length (SequestHT only): 6; precursor mass tolerance: 15 ppm; 
fragment mass tolerance: 0.05 Da; static modifications: Carbamidomethyl (C); dynamic 
modifications: Oxidation (M); peptide-spectrum match (PSM) validator: Target Decoy or 
Percolator (Mascot and Sequest HT only) or Decoy Fusion (PEAKS only); target FDR: 0.01. 
Evaluation of the respective capacity of Mascot and Sequest HT to identify peptides from 
mass spectra was performed by comparing the results from two different scoring functions for 
PSM-validation; the Percolator algorithm (21, 22) and a regular target decoy (TD) validator 
(23), both implemented in the software Proteome Discoverer 2.0 (Thermo). 
Confirmation of identification of tau endogenous peptides in CSF 
Two synthetic, stable isotope-labelled peptides, NH2-TPPAPKTPSSGEPP[K(13C6)]-COOH 
and NH2-TPPAPK[T(PO3H2)]PSSGEPP[K(13C6)]-COOH, corresponding to amino acids 
175-190 of microtubule-associated protein tau, were custom synthesized (AQUA peptides; 
Thermo Scientific) to confirm the identification of their native counterparts. 50 fmol each of 
175NH2-TPPAPKTPSSGEPP[K(13C6)]-COOH190 and 175NH2-
TPPAPK[T(PO3H2)]PSSGEPP[K(13C6)]-COOH190 were spiked into the endogenous sample 
corresponding to 1.5 ml CSF following pre-treatment but prior to fractionation. 
Results and Discussion 
To increase the number of identified endogenous peptides in CSF we supplemented a previously 
developed protocol (19, 24), based on molecular weight ultrafiltration, with an additional peptide 
fractionation step employing high-pH reversed-phase chromatography according to the method 
described by Batth and colleagues (20). Besides reducing sample complexity, pre-fractionation 
enabled us to use a fivefold larger volume of CSF for nano-LC-MS analysis compared to our previous 
studies, permitting the detection of lower-abundant peptides. We also evaluated software programs 
that use different strategies for peptide identification and validation of PSMs. Identified peptides were 
evaluated based on previously reported association to neurodegenerative disorders and peptides of 
particular interest (i.e., derived known or potential biomarkers) were examined further. 
Peptide identification 
The identification success rate is generally lower for endogenous peptides than for tryptic 
peptides. An LC-MS data set of tryptic peptides from CSF, consisting of 427,613 MS/MS 
spectra, resulted in 36,886 confident (FDR<1%) PSMs, corresponding to 8.6% identified 
spectra, while a set of endogenous CSF peptides, consisting of 269,945 MS/MS spectra, 
yielded 3,094 accepted PSMs, i.e., only 1.1% identified spectra. A reason for the lower 
identification rate for endogenous peptides may be that they differ in composition compared 
to tryptic peptides: for example, they are on average longer, and contain lysine and arginine 
residues internally but not necessarily at the C-terminus. Thus PSM scoring algorithms 
optimized for tryptic peptides may not be optimal for endogenous peptides. To test this 
hypothesis, we searched LC-MS data from one sample (12 HpH-RPLC fractions) with the 
software programs Mascot (25, 26) and SequestHT (27, 28), which are based on fragment ion 
fingerprinting (26, 29), for both programs using either the default scoring algorithm or the 
Percolator algorithm (21, 30). While both algorithms use the target/decoy approach to assess 
the correctness of PSMs, Percolator employs machine learning to improve the base scoring 
algorithm based on a subset of highly confident PSMs in an iterative process. Thereby, the 
algorithm can adapt to the general fragmentation characteristics of peptides in the given 
sample and mass spectrometric experiment. Mascot identified 1,276 endogenous peptides 
using the default algorithm, and 8,679 peptides using Percolator, corresponding to over a 6-
fold increase (Figure 1A). Sequest HT identified 1,694 endogenous peptides using its default 
scoring algorithm, and improved more than four-fold, to 7,288 peptides when instead 
applying Percolator (Figure 1B). For tryptic peptides the differences between Percolator and 
the default scoring algorithms were smaller: Mascot identified 5,824 peptides using the 
default algorithm and 7,926 peptides using Percolator, corresponding to an increase of 36% 
(Figure 1C), and SequestHT 7,028 peptides using the default algorithm and 7,917 using 
Percolator, corresponding to an increase of 12% (Figure 1D). 
Another difference regarding identification of endogenous peptides compared to tryptic 
peptides is that no enzymatic cleavage can be specified in the database search. Thereby, the 
number of peptide sequences to evaluate increases by a factor of 100-1,000, increasing the 
occurrence of incorrect PSMs. De novo sequencing is an alternative to fragment ion 
fingerprinting for peptide identification, in which partial peptide sequences are extracted by 
using intrinsic m/z information in MS/MS spectra (31). Because this approach does not rely 
on knowledge of the amino acids at the peptide termini, we hypothesized that it may be more 
successful for identification of endogenous peptides. To test this hypothesis, we searched the 
LC-MS data from the previous section using PEAKS Studio (32), which identifies peptides by 
de novo sequencing followed by a tag search (33, 34), and uses a PSM validator which 
combines machine learning and target decoy functions, some of which are also featured in 
Percolator, in a decoy fusion PSM validator (35). PEAKS identified 10,967 peptides (1% 
FDR), i.e., nearly 2,500 peptides more than Mascot and more than 3,000 peptides more than 
SequestHT (Figure 2).  
The identification overlap between PEAKS and the data-dependent search engines was quite 
small. Compared to 70% peptide identification conformity between Mascot and Sequest HT, 
the identification overlap between PEAKS and either of the other two search engines was less 
than 20%, and the total overlap between all three was less than 15% (Figure 2). The number 
of peptides identified with the different programs and scoring algorithms are listed in Table 1. 
The small overlap between the fingerprinting and de novo based methods raises the question 
of whether the identifications are correct or not. While correctness cannot be directly tested in 
this data set, for the subset of MS/MS spectra with assigned PSMs in at least two programs, 
the percent discrepant PSM assignments between the programs could reveal if the actual FDR 
of either of the programs is higher than the target value. The discrepancies between the 
programs were below 2% in all cases, thus not indicating erroneous FDR (Table 2). 
In conclusion, for identification of endogenous peptides by fragment ion fingerprinting, the 
optimal scoring algorithm differs from that of tryptic peptides, and a significant improvement 
can be achieved by using an adaptive scoring approach such as Percolator. Further, our results 
show that peptide identification based on de novo sequencing and fragment ion fingerprinting 
are complementary and should be used in combination for increased number of identified 
peptides. 
Evaluation of biomarker candidates 
Combining the results from the two CSF samples searched by three search engines resulted in a total 
of 18,031 unique endogenous peptides (FDR=1%), derived from 1,918 proteins. The set of proteins 
identified in our study was compared to CSF biomarkers and biomarker candidates presented in four 
recent review articles (3, 10, 36, 37) (see Table 3). 
Microtubule-Associated Protein Tau 
Among the identified endogenous peptides of particular interest were five derived from 
microtubule-associated protein tau (Table 4, Figure 3). In humans the primary role of tau is to 
stabilise neuronal microtubules, which are vital to axonal transport (38, 39). Intraneuronal 
aggregation of tau in the brain is involved in several neurodegenerative diseases, which are 
collectively referred to as tauopathies (40, 41). A specific pathophysiological trait of AD is 
phosphorylation of one or several tau-motifs (42-44), resulting in so-called 
hyperphosphorylated tau (p-tau). Hyperphosphorylation causes tau to dissociate from the 
microtubule-network, leading to its breakdown, and eventually results in cell-death (44, 45), 
resulting in increased CSF tau level (46-48). Together with the amyloid beta 1-42 peptide 
(Aβ1-42), total tau (t-tau) and p-tau can be used to diagnose AD with high sensitivity and 
specificity (1, 37, 48, 49).  
A study in which fractionated CSF proteins were analysed by Western blot demonstrated the 
existence of a multitude of tau protein fragments spanning a wide molecular weight range 
(47). The data indicated differences in the abundance of several fragments between AD 
patients and controls, suggesting that it may be important to study the disease association of 
specific tau fragments or endogenous tau peptides. Our study is the first to report endogenous 
tau peptides in human CSF. Interestingly, four of the identified peptides (tau 175-189, tau 
175-190, tau 175-193 and tau 176-190) span Thr-181, which is the phosphorylation site 
detected by the most commonly used immunoassay for p-tau (50). The identity of tau 175-190 
was verified by spiking a CSF sample with custom synthesized tau 175-190 and analysing by 
LC-MS (Figure 4). Additionally, tau 175-190 with phosphorylated Thr-181 was spiked in, 
demonstrating also the presence of the phosphorylated form in CSF (data not shown). Further 
studies are under way to evaluate the performance of tau 175-190 and p-tau 175-190 as 
biomarkers of AD and other tauopathies.   
Amyloid   
A total of 213 peptides belonging to the amyloid precursor protein (APP) were identified. Of 
these, 58 were located fully or partly within the APP672-713 (APP770; identifier: P05067-1) 
sequence, corresponding to Aβ1-42, the main constituent of amyloid plaques, one of the 
hallmark pathological lesions of AD (Supplemental Table s1). A majority of the truncated, 
endogenous Aβ peptide forms we report on here have been previously identified using a 
combination of immunoprecipitation (IP) and MS (51, 52). However; we identified a number 
of truncated segments not previously reported, in some cases likely because their sequences 
were outside the epitopes of the antibodies (12EF325, 6E10, and 4G8) used. A further three 
peptides (-10 to 9, -15 to 9 and -8 to 2) were not completely located within the Aβ sequence. 
Endogenous peptides located within the Aβ1-42 sequence are of particular interest when 
studying enzymatic processing of the Aβ/APP, e.g., to confirm target engagement of beta-
secretase inhibitor treatment (53) 
Apolipoprotein E 
109 endogenous peptides derived from apoE were identified (Supplemental Table s1). Apolipoprotein 
E (apoE) is a glycoprotein which known functions involve CNS lipid transport and peripheral 
circulation (54). It is also believed to be a “progenitor” for bioactive polypeptides resulting from 
proteolytic cleavage of the protein (55-57). ApoE is known to be involved in AD and other 
neurodegenerative diseases (58-60), and there is evidence suggesting the protein affects AD through 
interaction with Aâ1-42 (61, 62), but the exact mechanism is still not fully understood. 
There are three major isoforms of apoE in humans which differ by two single-amino acid 
substitutions: å2 - Cys130/Cys176; å3 - Cys130/Arg176 and å4 - Arg130/Arg176. Carrying at least one allele 
å4 of the APOE gene (APOE) correlates with an increased risk of developing AD (58, 60, 63), whilst 
å2 (APOE2) seems to have a neuroprotective function (62, 64), and å3 (APOE3) is neutral in terms of 
AD risk (60). 
We identified 109 endogenous apoE peptides covering >70% of the protein-sequence. Among 
the identified peptides were 6 spanning AA-130, and 3 spanning AA-176 allowing for 
separate quantification of endogenous peptides produced from the different genetic variants in 
future studies.  
 
Conclusions 
The described sample preparation, peptide fractionation, and peptide identification using 
different search engines significantly expanded the known CSF peptidome. The large number 
of endogenous CSF peptides identified, many of which have been reported to be associated 
with neurodegenerative diseases and comprising also peptides from low-abundant proteins, 
strongly suggests that this class of molecules is a promising source of biomarkers to explore 
in clinical studies. 
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 Tables 
 
Table 1. Number of endogenous CSF peptides identified using Mascot and SequestHT with 
Percolator or the default scoring algorithms, or PEAKS. 
 
Protein identification 
software 
Scoring algorithm Number of identified 
peptides 
Default 1,276 / 5,824 Mascot 
(endogenous / tryptic) Percolator 8,679 / 7,926 
Default 1,694 / 7,028 Sequest HT 
(endogenous / tryptic) Percolator 7,288 / 7,917 
PEAKS 
(endogenous) 
De novo-sequencing/ 
Target Decoy Fusion / 10,967 
 
Table 2. Discrepancy between protein identification software. 
 
Identification 
software compared 
# Mutual 
peptide IDs 
# Identical 
peptide ID/Scan 
# Peptide ID 
discrepancies 
Peptide ID 
discrepancy (%)
Mascot - PEAKS 18,337 17,984 353 1.93 
SequestHT - PEAKS 16,108 16,044 64 0.40 
Mascot - SequestHT 17,323 17,235 88 0.51 
 
Table 3. 
 
Protein Acc. No. Disease # Peptides identified 
Secretogranin-1 P05060 AD, PD (10) 681 
Clusterin P10909 AD, MS, PD (10) 318 
Amyloid beta A4 protein P05067 AD, CJD (3) 213 
SeroTransferrin 
(Transferrin, Beta-1 
metal-binding globulin)  
P02787 AD, MS (3, 10) 189 
SPARC-like protein 1 Q14515 AD, MS (10) 179 
ProSAAS Q9UHG2 AD, MS (10) 153 
Cystatin-C P01034 AD, PD (3, 10) 140 
Prostaglandin-H2 D-
isomeras (Beta-trace 
protein)  
P41222 
AD, MS, Spinal canal 
stenosis, Bacterial meningitis
(3, 10) 
123 
Apolipoprotein E P02649 AD, MS (3, 10) 109 
Beta-2-microglobulin P61769 AD, MS, PD (10) 96 
Complement C3 P01024 AD, MS (10) 65 
Neuronal pentraxin 
receptor O95502 AD, MS, PD (10) 65 
Complement C4-A P0C0L4 AD, MS (10) 62 
Superoxide dismutase 
[Cu-Zn] P00441 AD, PD, MS (10) 61 
Transthyretin (ATTR, 
Prealbumin) P02766 AD, PD, MS (3, 10) 61 
Fibrinogen beta chain P02675 AD, PD (10) 56 
GAP43 (neuromodulin) P17677 AD (36) 39 
Vitamin D-binding 
protein P02774 AD, PD, MS (10) 38 
Gelsolin P06396 AD, MS, PD (10) 37 
Insulin-like growth 
factor-binding protein 5 P24593 AD, PD (10) 37 
Zinc-alpha-2-glycoprotein P25311 AD, PD, MS (10) 37 
Alpha-1B-glycoprotein P04217 AD, MS, PD (10) 31 
Beta-2-glycoprotein 1 P02749 AD, PD (10) 31 
Actin, cytoplasmic 1 P60709 AD, MS (10) 23 
Apolipoprotein D P05090 AD, MS (3, 10) 23 
Alpha-1-Antitrypsin P01009 AD, MS (10) 22 
Contactin-1 Q12860 AD, MS (10) 22 
Alpha-1-acid glycoprotein 
1 (Orosomucoid 1) P02763 AD, MS, PD (10) 21 
Retinol-binding protein 4 P02753 AD, MS, PD (10) 21 
Polymeric 
immunoglobulin receptor P01833 AD, PD (10) 18 
Kallikrein-6 Q92876 AD, MS, PD (10) 17 
Serum amyloid A protein 
precursor P0DJI8 AD, PD (10) 17 
Somatostatin P61278 AD, Depression (3) 17 
EGF-containing fibulin-
like extracellular matrix  
protein 1 
Q12805 AD, MS (10) 15 
Cell growth regulator 
with EF-hand domain 
protein 1 
Q99674 AD, PD (10) 14 
Dystroglycan Q14118 AD, MS (10) 14 
Angiotensinogen P01019 AD, MS, PD (10) 13 
IL-6 soluble receptor P40189 AD, Stroke (3) 13 
Adherens junction-
associated protein 1 Q9UKB5 AD, PD (10) 12 
Ceruloplasmin P00450 AD, MS, PD (10) 11 
Neurofilament medium 
polypeptid P07197 MS, MSA (3) 10 
72 kDa type IV 
collagenase P08253 MS, PD (10) 9 
Insulin-like growth factor 
binding protein-3 P17936 CNS tumours (3) 8 
Hypocretin-1 (Orexin-A) O43612 Narcolepsy (3) 7 
Synaptotagmin-1  P21579 AD (3) 7 
Creatine kinase B-type  P12277 CJD (3) 6 
Microtubule-associated 
protein tau P10636 AD, CJD, PD (3) 5 
Myelin basic protein  P02686 MS (3) 5 
Neurexin-1-alpha Q9ULB1 AD, PD (10) 5 
Pigment epithelium-
derived factor P36955 AD, ALS, MS, PD (3, 10) 5 
Pro-opiomelanocortin  P01189 Infantile Autism (3) 5 
Alpha-2-macroglobulin P01023 MS, PD (10) 4 
Disintegrin and 
metalloproteinase 
domain-containing 
protein 17 
P78536 AD (3) 4 
132 kDa protein 
(Transcriptional-
regulating factor 1) 
Q96PN7 AD, PD (10) 3 
Acyl-CoA-binding 
protein P07108 AD (3) 3 
Neurospecific enolase  P09104 CJD (36) 3 
14-3-3 protein P31947 CJD (3) 2 
BACE2 Q9Y5Z0 AD (37) 2 
Neurogranin Q92686 AD (37) 2 
Cochlin O43405 AD, PD (10) 1 
Glutamine Synthetase P15104 AD (3) 1 
Neurofilament heavy 
polypeptide P12036 MS, MSA (3) 1 
Neurofilament light 
polypeptide P07196 MS; MSA (36) 1 
Visinin-like protein 1  P62760 AD (37) 1 
Table 4. Endogenous peptides identified from microtubule-associated protein Tau. The amino 
acid sequence position corresponds to isoform Tau-F (Protein accession nr. P10636-8). 
 
 Position Sequence Charge MW (monoisotopic) [Da] 
171-180 IPAKTPPAPK 2 1018.62 
175-189 TPPAPKTPPSSGEPP 2 1458.74 
175-190 TPPAPKTPPSSGEPPK 2/3 1586.83 
209-224 SRTPSLPTPPTREPK 3 1662.90 
212-224 TPSLPTPPTREPK 3 1419.77 
 
 
 
Figure legends 
 
Figure 1. 
Comparison of number of identified endogenous (A, C) and tryptic (B, D) peptides with 
Mascot (A, B) and SequestHT (C, D). PSM were scored using the default scoring algorithm 
of the respective software (blue) as well as the machine learning-based algorithm, Percolator 
(yellow). 
 
Figure 2. 
Comparison of number of identified endogenous peptides with Mascot, Sequest HT, and 
PEAKS Studio. 
 
Figure 3. 
Endogenous peptides identified from microtubule-associated protein Tau (Accession no. 
P10636-8). The sequence of isoform Tau-F (441 aa) is shown. 
 
Figure 4. 
Identification verification of endogenous Tau 175-190 by spiking CSF with synthetic heavy 
isotope labelled peptide 175NH2-TPPAPKTPSSGEPPK(13C6)-COOH190  (+6 Da). (A) XIC of 
heavy labelled (top) and endogenous (bottom) peptides shows co-elution. (B) The endogenous 
and heavy labelled peptide signals (M+2H2+) are separated by 3 m/z, as expected. (C) The 
endogenous (bottom) and heavy (top) labelled peptides display similar fragment ion patterns. 
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